Evidence map›Paper›PMID 33995026›Full record

ReviewFrontiers in pharmacology2021

Pharmacological Benefits of Triphala: A Perspective for Allergic Rhinitis.

Salinee Jantrapirom, Pannaphak Hirunsatitpron, Saranyapin Potikanond, Wutigri Nimlamool, Nutthiya Hanprasertpong

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Molecular mechanism of Dang-Shen-Yu-Xing decoction againstFrontiers in veterinary science · 2024
    Article
  7. Review
  8. Identification of bioactive molecules fromJournal of King Saud University. Science · 2022
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Salinee JantrapiromDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Pannaphak HirunsatitpronDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Saranyapin PotikanondDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Wutigri NimlamoolDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Nutthiya HanprasertpongDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Chiang Mai University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic rhinitis (AR) is considered a major nasal condition impacting a large number of people around the world, and it is now becoming a global health problem. Because the underlying mechanisms of AR are complex, the development of single-drug treatment might not be enough to treat a wide spectrum of the disease. Although the standard guidelines classify and provide suitable diagnosis and treatment, the vast majority of people with AR are still without any means of controlling it. Moreover, the benefits of AR drugs are sometimes accompanied by undesirable side effects. Thus, it is becoming a significant challenge to find effective therapies with limited undesirable side effects for a majority of patients suffering from uncontrolled AR. Aller-7/NR-A2, a polyherbal formulation, has revealed promising results in patients by reducing nasal symptoms and eosinophil counts without serious adverse effects. Interestingly, three out of seven of the herbals in the Aller-7/NR-A2 formulation are also found in an Ayurvedic polyherbal formulation known as "Triphala," which is a potential candidate for the treatment of AR. However, there are no current studies that have examined the effects of Triphala on the disease. This review aims to describe the complexity of AR pathophysiology, currently available treatments, and the effects of Triphala on AR in order to help develop it as a promising alternative treatment in the future.

Indexed as

allergic rhinitisanti-inflamamtionantioxidant effectimmunomodulaiontriphala

Identifiers

PMID33995026
PMCPMC8120106
OpenAlexW3159720326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.